AstraZeneca plc will be Ironwood Pharmaceuticals Inc.'s development and commercialization partner for linaclotide in the vast China territory. Ironwood filed a clinical trial application with China's State Food and Drug Administration for a Phase III study of linaclotide in irritable bowel with constipation (IBS-C).